Back to Search Start Over

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

Authors :
R. Erdmann
Alexander Nast
Lajos Kemény
P.C.M. van de Kerkhof
Christopher E.M. Griffiths
J. Ferguson
Paolo Gisondi
SL Karvonen
Catherine H. Smith
Alessandro Giunta
Mara Maccarone
Sergio Chimenti
Ortonne Jp
Ina Kopp
Anthony Ormerod
Alan Menter
Jan D. Bos
Giampiero Girolomoni
Natalie Reytan
C. Leonardi
Ray Jobling
Luigi Naldi
Herbert Hönigsmann
Ulrich Mrowietz
Jonathan Barker
Taina Rantanen
Bernadette Eberlein
B. Rzany
D. Pathirana
Munther Hussain
Ph.I. Spuls
Philippe Saiag
L Dubertret
Kristian Reich
Tamar Nijsten
GR Burmester
Hans-Dieter Orzechowski
H Richards
H.B. Thio
Dermatology
Source :
Journal of the European Academy of Dermatology and Venereology, 23. Wiley-Blackwell, JEADV : Journal of the European Academy of Dermatology and Venereology, 23 Suppl 2, 1-70, JEADV : Journal of the European Academy of Dermatology and Venereology, 23 Suppl 2, 2, pp. 1-70
Publication Year :
2009

Abstract

Contains fulltext : 80789.pdf (Publisher’s version ) (Closed access) Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.

Details

ISSN :
09269959
Volume :
23
Database :
OpenAIRE
Journal :
Journal of the European Academy of Dermatology and Venereology
Accession number :
edsair.doi.dedup.....078d50662c0e8db79b66802de9287ef5
Full Text :
https://doi.org/10.1111/j.1468-3083.2009.03389.x